{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:08:34Z","timestamp":1792804114446,"version":"4.5.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"29","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["3P01AG027296-11S1"],"award-info":[{"award-number":["3P01AG027296-11S1"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["3P01AG027296-11S1"],"award-info":[{"award-number":["3P01AG027296-11S1"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["5U54AG063546-02S5"],"award-info":[{"award-number":["5U54AG063546-02S5"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.vaccine.2021.05.088","type":"journal-article","created":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T17:25:32Z","timestamp":1622222732000},"page":"3844-3851","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Adverse events following mRNA SARS-CoV-2 vaccination among U.S. nursing home residents"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9911-235X","authenticated-orcid":false,"given":"Barbara H.","family":"Bardenheier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6000-6859","authenticated-orcid":false,"given":"Stefan","family":"Gravenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5975-9164","authenticated-orcid":false,"given":"Carolyn","family":"Blackman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roee","family":"Gutman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indra Neil","family":"Sarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Feifer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"McConeghy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aman","family":"Nanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Mor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2021.05.088_b0005","unstructured":"The COVID Tracking Project. The Long-Term Care COVID Tracker. https:\/\/covidtracking.com\/nursing-homes-long-term-care-facilities (accessed 03\/18\/2021."},{"issue":"49","key":"10.1016\/j.vaccine.2021.05.088_b0010","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.15585\/mmwr.mm6949e1","article-title":"The Advisory Committee on Immunization Practices' Interim Recommendation for Allocating Initial Supplies of COVID-19 Vaccine - United States, 2020","volume":"69","author":"Dooling","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"27","key":"10.1016\/j.vaccine.2021.05.088_b0015","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.vaccine.2021.05.088_b0020","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.vaccine.2021.05.088_b0025","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.maturitas.2015.05.004","article-title":"Immunosenescence: implications for response to infection and vaccination in older people","volume":"82","author":"Pera","year":"2015","journal-title":"Maturitas"},{"key":"10.1016\/j.vaccine.2021.05.088_b0030","unstructured":"Centers for Disease Control and Prevention. COVID Data Tracker: Federal Pharmacy Partnership for Long-Term Care (LTC) Program. https:\/\/covid.cdc.gov\/covid-data-tracker\/#vaccinations-ltc (accessed 03\/10\/2021)."},{"key":"10.1016\/j.vaccine.2021.05.088_b0035","doi-asserted-by":"crossref","unstructured":"I. Torjesen. Covid-19: Norway investigates 23 deaths in frail elderly patients after vaccination. BMJ, vol. 372, p. n149, Jan 15 2021, doi: 10.1136\/bmj.n149.","DOI":"10.1136\/bmj.n149"},{"key":"10.1016\/j.vaccine.2021.05.088_b0040","unstructured":"Brighton Collaboration. Priority List of Adverse Events of Special Interest: COVID-19. The Task Force for Global Health. https:\/\/brightoncollaboration.us\/wp-content\/uploads\/2021\/01\/SO2_D2.1.2_V1.2_COVID-19_AESI-update-23Dec2020-review_final.pdf (accessed 03\/11\/2021)."},{"issue":"36","key":"10.1016\/j.vaccine.2021.05.088_b0045","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)","volume":"33","author":"Shimabukuro","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.05.088_b0050","unstructured":"Centers for Disease Control and Prevention. Rapid Cycle Analysis (RCA) to monitor the safety of COVID-19 vaccines in near real-time within the Vaccine Safety Datalink. Rapid Cycle Analysis (RCA) to monitor the safety of COVID-19 vaccines in near real-time within the Vaccine Safety Datalink VSD Project #1342 (cdc.gov) (accessed 03\/31\/2021)."},{"issue":"2","key":"10.1016\/j.vaccine.2021.05.088_b0055","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1214\/ss\/1009213286","article-title":"Interval estimation for a binomial proportion - Comment - Rejoinder (in English)","volume":"16","author":"Brown","year":"2001","journal-title":"Stat Sci"},{"issue":"11","key":"10.1016\/j.vaccine.2021.05.088_b0060","doi-asserted-by":"crossref","first-page":"M546","DOI":"10.1093\/gerona\/54.11.M546","article-title":"Scaling ADLs within the MDS","volume":"54","author":"Morris","year":"1999","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"9","key":"10.1016\/j.vaccine.2021.05.088_b0065","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1097\/MLR.0000000000000334","article-title":"The Minimum Data Set 3.0 Cognitive Function Scale","volume":"55","author":"Thomas","year":"2017","journal-title":"Med Care"},{"issue":"2","key":"10.1016\/j.vaccine.2021.05.088_b0070","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2307\/1403146","article-title":"Model Robust Confidence-Intervals Using Maximum-Likelihood Estimators (in English)","volume":"54","author":"Royall","year":"1986","journal-title":"Int Stat Rev"},{"issue":"2","key":"10.1016\/j.vaccine.2021.05.088_b0075","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jeconom.2009.09.023","article-title":"Efficient semiparametric estimation of multi-valued treatment effects under ignorability (in English)","volume":"155","author":"Cattaneo","year":"2010","journal-title":"J Econometrics"},{"issue":"8","key":"10.1016\/j.vaccine.2021.05.088_b0080","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1001\/jama.2021.0600","article-title":"Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine","volume":"325","author":"Shimabukuro","year":"2021","journal-title":"JAMA"},{"issue":"42","key":"10.1016\/j.vaccine.2021.05.088_b0085","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1016\/j.vaccine.2014.07.073","article-title":"The Vaccine Safety Datalink: successes and challenges monitoring vaccine safety","volume":"32","author":"McNeil","year":"2014","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2021.05.088_b0090","doi-asserted-by":"crossref","first-page":"283","DOI":"10.15585\/mmwr.mm7008e3","article-title":"First Month of COVID-19 Vaccine Safety Monitoring - United States, December 14, 2020-January 13, 2021","volume":"70","author":"Gee","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21006836?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21006836?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T13:32:14Z","timestamp":1778679134000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21006836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":18,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S0264410X21006836"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.05.088","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adverse events following mRNA SARS-CoV-2 vaccination among U.S. nursing home residents","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.05.088","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}